SCHEMBL5216941

SCHEMBL5216941

Cc1cc2c(nc1Cl)N1[C@H](C2)CN(C(=O)OC(C)(C)C)C[C@H]1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 4/20 0.38
USP30 Q70CQ3 2/20 0.36
NAMPT P43490 1/20 0.35
PIK3CA P42336 3/20 0.35
NR1H2 P55055 1/20 0.35
P2RX3 P56373 1/20 0.35
KAT6A Q92794 1/20 0.35
KAT5 Q92993 1/20 0.35
POLB P06746 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
SSTR4 P31391 1/20 0.34
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34
APH1B Q8WW43 1/20 0.34
NCSTN Q92542 1/20 0.34
APH1A Q96BI3 1/20 0.34
PSENEN Q9NZ42 1/20 0.34
RET P07949 1/20 0.34
PIK3R1 P27986 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5219682 0.89 GPR119 (0.39) GPR119USP30NAMPTPIK3CANR1H2
SCHEMBL1983772 0.88 USP30 (0.40) GPR119USP30PIK3CAPOLBPSEN1
SCHEMBL5219194 0.87 GPR119 (0.38) GPR119USP30PIK3CAP2RX3KAT6A
SCHEMBL5218645 0.86 PIK3CD (0.38) GPR119USP30PIK3CASSTR4PIK3R1
SCHEMBL5219588 0.85 GPR119 (0.41) GPR119USP30NAMPTPIK3CANR1H2
SCHEMBL5218788 0.85 GPR119 (0.39) GPR119USP30PIK3CAP2RX3KAT6A
SCHEMBL5222138 0.85 GPR119 (0.36) GPR119USP30NAMPTPIK3CAP2RX3
SCHEMBL5221226 0.84 GPR119 (0.39) GPR119USP30NAMPTPIK3CANR1H2
SCHEMBL5226099 0.84 GPR119 (0.40) GPR119USP30PIK3CAMEN1KMT2A
SCHEMBL5218998 0.83 GPR119 (0.37) GPR119USP30PIK3CAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1641796-B1 5HT2C RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY HOFFMANN LA ROCHE (CH) 2007-06-06 EP disclosed
US-7208494-B2 5HT2c receptor agonists HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US disclosed
US-20050026925-A1 5HT2c receptor agonists HOFFMANN-LA ROCHE INC. 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026925-A1 5HT2c receptor agonists HTR2C, HTR2A, HTR5A GPR119 17/4885USP30 3134/4885NAMPT 3185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.